AFM
RNA

Anson Funds Management’s Atrium Therapeutics RNA Stock Holding History

Anson Funds Management’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
+125,000
New +$1.63M 0.1% 116

Other funds holding RNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $144M AUM 26.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $190M AUM 51.6% 1-Year Est. Return
SC
Slotnik Capital Dallas, Texas $387M AUM 106.2% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.8% 1-Year Est. Return
CDMG
Creek Drive Management Group San Francisco, California $206M AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Anson Funds Management's RNA Position: Q2 2026 in Review

Anson Funds Management opened a new position in Atrium Therapeutics (RNA) in Q2 2026: 125,000 shares worth $1.68M. The stake represents 0.1% of the portfolio and ranks #116 among its holdings.

95 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Anson Funds Management held 125,000 shares of Atrium Therapeutics worth $1.68M as of Q2 2026.
  • Atrium Therapeutics was a new Anson Funds Management position in Q2 2026.
  • Atrium Therapeutics made up 0.1% of Anson Funds Management's portfolio in Q2 2026, its #116 holding.
  • 95 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Anson Funds Management's 13F filing for Q2 2026, filed 13 Aug 2026.